https://www.yiliao.com/index.php?action=history&feed=atom&title=%E5%86%B7%E7%BC%BA%E8%A1%80%E6%97%B6%E9%97%B4
冷缺血时间 - 版本历史
2026-04-18T23:36:36Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E5%86%B7%E7%BC%BA%E8%A1%80%E6%97%B6%E9%97%B4&diff=312345&oldid=prev
2026年1月2日 (五) 00:30 77921020
2026-01-02T00:30:51Z
<p></p>
<a href="https://www.yiliao.com/index.php?title=%E5%86%B7%E7%BC%BA%E8%A1%80%E6%97%B6%E9%97%B4&diff=312345&oldid=312344">显示更改</a>
77921020
https://www.yiliao.com/index.php?title=%E5%86%B7%E7%BC%BA%E8%A1%80%E6%97%B6%E9%97%B4&diff=312344&oldid=prev
2026年1月2日 (五) 00:28 77921020
2026-01-02T00:28:39Z
<p></p>
<a href="https://www.yiliao.com/index.php?title=%E5%86%B7%E7%BC%BA%E8%A1%80%E6%97%B6%E9%97%B4&diff=312344&oldid=312343">显示更改</a>
77921020
https://www.yiliao.com/index.php?title=%E5%86%B7%E7%BC%BA%E8%A1%80%E6%97%B6%E9%97%B4&diff=312343&oldid=prev
2026年1月2日 (五) 00:26 77921020
2026-01-02T00:26:12Z
<p></p>
<a href="https://www.yiliao.com/index.php?title=%E5%86%B7%E7%BC%BA%E8%A1%80%E6%97%B6%E9%97%B4&diff=312343&oldid=312342">显示更改</a>
77921020
https://www.yiliao.com/index.php?title=%E5%86%B7%E7%BC%BA%E8%A1%80%E6%97%B6%E9%97%B4&diff=312342&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #334155; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-02T00:23:37Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #334155; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #334155; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<h2 style="border-left: 6px solid #1e40af; background: linear-gradient(to right, #eff6ff, #ffffff); color: #1e3a8a; padding: 12px 20px; font-size: 1.25em; margin-top: 40px; font-weight: bold; border-radius: 0 8px 8px 0;">典型谱系：临床四大“免疫荒漠”</h2><br />
<br />
<p style="margin: 15px 0 25px 0; text-align: justify; color: #475569;"><br />
以下四类肿瘤是临床最典型的原发性耐药代表。新一代疗法正针对其独特的“荒漠化”机制（如物理屏障、信号缺陷）进行精准突围。<br />
</p><br />
<br />
<div style="overflow-x: auto; margin-bottom: 30px; border-radius: 8px; box-shadow: 0 10px 15px -3px rgba(0, 0, 0, 0.1), 0 4px 6px -2px rgba(0, 0, 0, 0.05); border: 1px solid #e2e8f0;"><br />
<table style="width: 100%; border-collapse: collapse; font-size: 0.95em; text-align: left; background-color: #ffffff;"><br />
<br />
<thead><br />
<tr style="background-color: #1e3a8a; color: #ffffff;"><br />
<th style="padding: 16px 20px; font-weight: 600; width: 22%; border-right: 1px solid #3b82f6;">肿瘤类型</th><br />
<th style="padding: 16px 20px; font-weight: 600; width: 43%; border-right: 1px solid #3b82f6;">荒漠化核心壁垒 (Barrier)</th><br />
<th style="padding: 16px 20px; font-weight: 600; width: 35%;">临床破局策略 (Breakthrough)</th><br />
</tr><br />
</thead><br />
<br />
<tbody><br />
<br />
<tr style="border-bottom: 1px solid #e2e8f0;"><br />
<td style="padding: 18px 20px; vertical-align: top; background-color: #f8fafc;"><br />
<div style="font-size: 1.05em; font-weight: bold; color: #0f172a;">胰腺导管腺癌</div><br />
<div style="font-size: 0.85em; color: #64748b; margin-top: 4px;">PDAC</div><br />
</td><br />
<td style="padding: 18px 20px; vertical-align: top; border-right: 1px solid #f1f5f9;"><br />
<span style="background-color: #fee2e2; color: #991b1b; padding: 2px 8px; border-radius: 4px; font-size: 0.85em; font-weight: bold;">物理屏障</span><br />
<p style="margin: 8px 0 0 0; line-height: 1.5; color: #334155;"><br />
极度致密的纤维化基质（Desmoplasia）如同“城墙”，物理阻隔 T 细胞浸润；同时富含 MDSC 抑制细胞。<br />
</p><br />
</td><br />
<td style="padding: 18px 20px; vertical-align: top;"><br />
<span style="background-color: #dcfce7; color: #166534; padding: 2px 8px; border-radius: 4px; font-size: 0.85em; font-weight: bold;">基质耗竭</span><br />
<p style="margin: 8px 0 0 0; line-height: 1.5; color: #334155;"><br />
联合 <strong>AG化疗</strong> (白蛋白紫杉醇+吉西他滨)；研发中的 <strong>CD40激动剂</strong>。<br />
</p><br />
</td><br />
</tr><br />
<br />
<tr style="border-bottom: 1px solid #e2e8f0;"><br />
<td style="padding: 18px 20px; vertical-align: top; background-color: #ffffff;"><br />
<div style="font-size: 1.05em; font-weight: bold; color: #0f172a;">前列腺癌</div><br />
<div style="font-size: 0.85em; color: #64748b; margin-top: 4px;">Prostate Ca.</div><br />
</td><br />
<td style="padding: 18px 20px; vertical-align: top; border-right: 1px solid #f1f5f9;"><br />
<span style="background-color: #e0f2fe; color: #075985; padding: 2px 8px; border-radius: 4px; font-size: 0.85em; font-weight: bold;">信号缺失</span><br />
<p style="margin: 8px 0 0 0; line-height: 1.5; color: #334155;"><br />
TMB 极低（缺乏靶标）+ <strong>PTEN缺失</strong>。PTEN 丢失导致 PI3K 通路激活，直接抑制抗原呈递机制。<br />
</p><br />
</td><br />
<td style="padding: 18px 20px; vertical-align: top;"><br />
<span style="background-color: #dcfce7; color: #166534; padding: 2px 8px; border-radius: 4px; font-size: 0.85em; font-weight: bold;">合成致死</span><br />
<p style="margin: 8px 0 0 0; line-height: 1.5; color: #334155;"><br />
联合 <strong>[[PARP抑制剂]]</strong> (如奥拉帕利)；或采用 <strong>PSMA</strong> 靶向放射配体疗法。<br />
</p><br />
</td><br />
</tr><br />
<br />
<tr style="border-bottom: 1px solid #e2e8f0;"><br />
<td style="padding: 18px 20px; vertical-align: top; background-color: #f8fafc;"><br />
<div style="font-size: 1.05em; font-weight: bold; color: #0f172a;">MSS 结直肠癌</div><br />
<div style="font-size: 0.85em; color: #64748b; margin-top: 4px;">MSS CRC</div><br />
</td><br />
<td style="padding: 18px 20px; vertical-align: top; border-right: 1px solid #f1f5f9;"><br />
<span style="background-color: #ffedd5; color: #9a3412; padding: 2px 8px; border-radius: 4px; font-size: 0.85em; font-weight: bold;">WNT 激活</span><br />
<p style="margin: 8px 0 0 0; line-height: 1.5; color: #334155;"><br />
APC 突变激活 WNT/β-catenin 通路，直接抑制 DC 细胞的招募，导致 T 细胞无法在淋巴结启动 (Priming Failure)。<br />
</p><br />
</td><br />
<td style="padding: 18px 20px; vertical-align: top;"><br />
<span style="background-color: #dcfce7; color: #166534; padding: 2px 8px; border-radius: 4px; font-size: 0.85em; font-weight: bold;">微环境调节</span><br />
<p style="margin: 8px 0 0 0; line-height: 1.5; color: #334155;"><br />
联合 <strong>[[抗血管生成]] TKI</strong> (如瑞戈非尼、呋喹替尼) 调节微环境。<br />
</p><br />
</td><br />
</tr><br />
<br />
<tr><br />
<td style="padding: 18px 20px; vertical-align: top; background-color: #ffffff;"><br />
<div style="font-size: 1.05em; font-weight: bold; color: #0f172a;">小细胞肺癌</div><br />
<div style="font-size: 0.85em; color: #64748b; margin-top: 4px;">SCLC</div><br />
</td><br />
<td style="padding: 18px 20px; vertical-align: top; border-right: 1px solid #f1f5f9;"><br />
<span style="background-color: #f3e8ff; color: #6b21a8; padding: 2px 8px; border-radius: 4px; font-size: 0.85em; font-weight: bold;">呈递缺陷</span><br />
<p style="margin: 8px 0 0 0; line-height: 1.5; color: #334155;"><br />
<strong>高TMB悖论</strong>：尽管因吸烟导致高突变，但 MHC-I 类分子普遍下调，“空有抗原，无法呈递”。<br />
</p><br />
</td><br />
<td style="padding: 18px 20px; vertical-align: top;"><br />
<span style="background-color: #dcfce7; color: #166534; padding: 2px 8px; border-radius: 4px; font-size: 0.85em; font-weight: bold;">不依赖 MHC</span><br />
<p style="margin: 8px 0 0 0; line-height: 1.5; color: #334155;"><br />
使用 <strong>[[DLL3双抗]]</strong> (Tarlatamab)，物理拉动 T 细胞杀伤，无需 MHC 参与。<br />
</p><br />
</td><br />
</tr><br />
<br />
</tbody><br />
</table><br />
</div><br />
<br />
</div></div>
77921020